Monopar Therapeutics Inc. (MNPR) Reports $6.2M Q3 Net Loss, Cash Runway to March 2028
Monopar reported a Q3 2026 net loss of $6.2M, or $0.72 per share, versus $3.4M, or $0.48 per share, in Q3 2025. Cash, cash equivalents and investments were $129.4M at September 30, 2026; the company expects funds to last through at least March 31, 2028.Material DetailsContext by AI AnalystThis is a…